IDEXX Laboratories, Inc. $IDXX Holdings Lifted by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 56.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 147,447 shares of the company’s stock after purchasing an additional 53,318 shares during the period. Westfield Capital Management Co. LP’s holdings in IDEXX Laboratories were worth $99,752,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC grew its position in IDEXX Laboratories by 2.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock worth $397,000 after purchasing an additional 15 shares during the last quarter. Harbour Investments Inc. grew its position in IDEXX Laboratories by 13.3% in the 4th quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock worth $92,000 after purchasing an additional 16 shares during the last quarter. CWA Asset Management Group LLC grew its position in IDEXX Laboratories by 3.5% in the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock worth $344,000 after purchasing an additional 17 shares during the last quarter. Stratos Wealth Partners LTD. grew its position in IDEXX Laboratories by 1.7% in the 3rd quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company’s stock worth $683,000 after purchasing an additional 18 shares during the last quarter. Finally, Cary Street Partners Investment Advisory LLC grew its position in IDEXX Laboratories by 11.5% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock worth $111,000 after purchasing an additional 18 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Citigroup initiated coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price for the company. Barclays reduced their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Finally, Piper Sandler reduced their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Trading Up 0.7%

Shares of NASDAQ:IDXX opened at $564.74 on Friday. The company has a 50 day moving average of $563.32 and a 200-day moving average of $632.63. The firm has a market cap of $44.55 billion, a P/E ratio of 41.59, a P/E/G ratio of 3.07 and a beta of 1.55. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the prior year, the business posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.